Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges

C. H. Masterson1,2, A. Ceccato3,4, A. Artigas4,5, C. dos Santos6,7, P. R. Rocco8,9, S. Rolandsson Enes10, D. J. Weiss11, D. McAuley12,13, M. A. Matthay14,15, K. English16,17, G. F. Curley18 and J. G. Laffey1,2,19*

Abstract

Severe viral pneumonia is a significant cause of morbidity and mortality globally, whether due to outbreaks of endemic viruses, periodic viral epidemics, or the rarer but devastating global viral pandemics. While limited anti-viral therapies exist, there is a paucity of direct therapies to directly attenuate viral pneumonia-induced lung injury, and management therefore remains largely supportive. Mesenchymal stromal/stem cells (MSCs) are receiving considerable attention as a cytotherapeutic for viral pneumonia. Several properties of MSCs position them as a promising therapeutic strategy for viral pneumonia-induced lung injury as demonstrated in pre-clinical studies in relevant models. More recently, early phase clinical studies have demonstrated a reassuring safety profile of these cells. These investigations have taken on an added importance and urgency during the COVID-19 pandemic, with multiple trials in progress across the globe. In parallel with clinical translation, strategies are being investigated to enhance the therapeutic potential of these cells in vivo, with different MSC tissue sources, specific cellular products including cell-free options, and strategies to ‘licence’ or ‘pre-activate’ these cells, all being explored. This review will assess the therapeutic potential of MSC-based therapies for severe viral pneumonia. It will describe the aetiology and epidemiology of severe viral pneumonia, describe current therapeutic approaches, and examine the data suggesting therapeutic potential of MSCs for severe viral pneumonia in pre-clinical and clinical studies. The challenges and opportunities for MSC-based therapies will then be considered.

Keywords: Cell therapy, Mesenchymal stem cells, Pneumonia, Coronavirus, Influenza, Acute respiratory distress syndrome, Sepsis, Critical Illness, Pandemic, Acute hypoxic respiratory failure

Introduction

Severe viral pneumonia is a significant cause of morbidity and mortality globally – one need look no further than the current COVID-19 pandemic to appreciate this. Outside of pandemic settings, viral-induced pneumonias remain common, both due to periodic epidemics, and from seasonal outbreaks of endemic disease. While anti-viral therapies exist, there is a paucity of direct therapies to directly attenuate viral pneumonia-induced...
lung injury. Management therefore remains largely supportive, including assistance with gas exchange and management of complications and super-infections.

Mesenchymal stromal/stem cells (MSCs) can be isolated from several tissues, such as bone marrow, adipose tissue, and umbilical cord[1, 2], and are receiving considerable attention as a cytotherapeutic for viral pneumonia. Several properties of MSCs position them as a promising therapeutic strategy for viral pneumonia-induced lung injury. Early phase clinical studies have demonstrated a reassuring safety profile of these cells when administered to healthy and ill patients. In addition, strategies are being investigated to enhance the therapeutic potential of these cells in vivo, with different tissue sources, cellular products (cell-free options), and methods of ‘licencing’ or ‘pre-activation’ of these cells, all being explored.

The aim of this review is to assess the therapeutic potential of MSC-based therapies for severe viral pneumonia of different aetiologies. It will describe the aetiology and epidemiology of severe viral pneumonia, describe current therapeutic approaches, and examine the data suggesting therapeutic potential of MSCs for severe viral pneumonia in pre-clinical and clinical studies. The challenges and opportunities for MSC-based therapies will then be considered.

Aetiology and epidemiology of severe viral pneumonia

Viruses are an increasingly frequent cause of pneumonia [3] in the general population. Before the COVID-19 pandemic, rhinovirus (23.6%), parainfluenza (20.8%), metapneumovirus (18.1%), influenza (16.7%) and respiratory syncytial virus (13.9%) were the main viral causes of severe pneumonia [4] (Table 1).

Influenza Virus A and B are common causes of severe pneumonia mainly in the fall or winter seasons. In the USA, it is estimated that influenza caused 38,000,000 cases in 2019–2020 season and 22,000 deaths [5]. Worldwide it is estimated that influenza causes 4–9 deaths per 100,000 individuals annually [6]. Over 10% of influenza patients require ICU admission. Severe disease develops mainly in patients with increased age and underlying conditions [7–9], due to isolated influenza infection or by a secondary bacterial co-infection, frequently with *Staphylococcus aureus* (often methicillin-resistant) or *Streptococcus pneumoniae* [10].

Influenza can cause pandemic disease. In 1918 Spanish flu caused 20–100 million deaths worldwide [11]. In 2009, the Swine-Origin Influenza A (H1N1) virus pandemic started in Mexico [12] and rapidly spread worldwide. Influenza A H1N1 caused severe disease with pneumonia and acute respiratory distress syndrome (ARDS) and

| Table 1 Viral causes of severe pneumonia |
|-----------------------------------------|
| **Most common viruses**                 | **Less common viruses**                      |
| Rhinovirus                              | Adenovirus                                   |
| Parainfluenza virus                     | Varicella-Zoster virus                        |
| Metapneumovirus                         | Hanta virus                                  |
| Influenza                               |                                              |
| Respiratory syncytial virus             |                                              |
| Coronavirus                             |                                              |
extrapulmonary disease. Younger patients, female, immunosuppression, obesity and pregnancy were risk factors for severe disease [13]. ICU mortality in H1N1-infected patients was approximately 40% [12]. Avian-origin Influenza has also been reported to cause human disease in isolated cases, but to date widespread human dissemination has not occurred [14].

Since 2000, several novel coronaviruses (CoVs) causing severe pneumonia have emerged. In 2003, severe acute respiratory syndrome (SARS), caused by the novel SARS-CoV emerged in the southeast of China, spreading throughout southeast Asia. More than 8000 patients were diagnosed, with 774 deaths reported in 26 countries during 2003 [15]. Spread was rapid, with nosocomial outbreaks affecting health care workers a feature [16]. In 2012, Middle-Eastern respiratory syndrome (MERS), caused by MERS-CoV, was first isolated in Saudi Arabia [17]. Since 2012 MERS outbreaks have been reported in 27 countries and 35% of patients died [18].

The SARS-CoV2 virus, which emerged in Wuhan China in late 2019, and was declared a pandemic by the WHO in March 2020, has infected over 250 million people, with over 4.5 million deaths reported (likely underestimated) to date [19]. Older age, immunosuppression, obesity, diabetes, hypertension, COPD, higher renal and cardiovascular SOFA score components, lower PaO2/FiO2 ratio, neutrophilia, higher LDH, D-dimer and a shorter time between first symptoms and ICU admission are associated with mortality [20–22]. Patients requiring invasive mechanical ventilation have a 45% mortality [23], with up to 80% of patients over 80 years of age dying [24]. Long-term morbidity after COVID-19 (‘Long COVID’), with severe alteration on chest-CT, decreased pulmonary functions and quality of life, is widely reported [25, 26].

**Mechanisms of lung injury in viral pneumonia**

The alveolar–capillary unit is disrupted during severe viral pneumonia [27], with upregulation of pro-inflammatory mediators, infiltration of neutrophils and monocyte–macrophages into the vascular and alveolar compartments increasing capillary endothelial permeability, resulting in ARDS [27]. Notable differences exist in the biologic profile of COVID-19 relative to classical ARDS, with lower expression of interferons (IFNs) and an increase in thrombotic mediators [28]. An understanding of the viral replication cycle, and the associated host response, highlights the unique pathophysiology of viral pneumonia.

Influenza viruses may infect a variety of lung cells, including ciliated epithelial cells, type I and II alveolar cells, and immune cells [29]. Virus tropism is due to the ability of influenza viruses to bind different isoforms of sialic acid present on host cells via hyaluronidase. The higher virulence of some influenza subtypes (e.g. the “avian” H5N1) may also be related to their greater affinity for the sialyl-galactosyl residues present in the distal respiratory tract, thus leading to more severe lung involvement [29].

The coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) exploit distinct receptors to enter host cells. MERS-CoV binds to the dipeptidyl peptidase-4 (DPP4), a surface protein mainly expressed on alveolar macrophages and, to a lesser extent, on alveolar epithelial cells and T cells [30, 31]. This marked tropism for immune rather than lung cells is the basis of MERS-CoV immunopathogenesis. SARS-CoV-2 has tropism for ciliated airway epithelial cells and type II alveolar epithelial cells, which is
conferred by its dependence on both the human angiotensin converting enzyme-2 (ACE2) receptor, as well as the host transmembrane serine protease-2 (TMPRSS2) for S-protein cleavage and subsequent activation [32]. An important, receptor-mediated pathogenic process derives from the dysregulation of the renin–angiotensin system (RAS) induced by SARS-CoV and SARS-CoV-2. By binding to ACE2, they induce both its internalization and shedding through ADAM17 activation; a reduced ACE2 activity results in increased vascular permeability, enhanced lung oedema, and worsening lung damage and the pro-inflammatory response [33, 34].

Upon viral sensing, pattern recognition receptors (PRRs), such as retinoic acid-inducible gene (RIG-I)-like receptors (RLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLR), such as NLRP3, activate signalling pathways that trigger the release of type I and III IFNs, as well as pro-inflammatory mediators, including cytokines, chemokines, and antimicrobial peptides, that assist in the prevention and clearance of respiratory viral infections [35]. The lung injury in the case of primary viral pneumonia is caused, in part, from the overproduction of inflammatory cytokines resulting from virus replication in lung cells [36]. Early work performed to characterize the host immune response of COVID-19 suggested an immune signature consisting of elevated serum cytokines [particularly Interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)-α], impaired interferon responses, and peripheral lymphopenia as markers of severe disease; other associated inflammatory serum markers include elevated levels of ferritin, lactate dehydrogenase, d-dimer, C-reactive protein, and coagulation factors [36, 37]. The pro-inflammatory immune signature of SARS-CoV-2 has been likened to macrophage-activation syndrome (MAS), a life-threatening clinical entity observed in autoimmune diseases and mimicked in many viral infections, including influenza [38, 39]. However, reported plasma IL-6 levels in COVID-19 patients appear to be significantly lower on average (10- to 40-fold) when compared with those reported in other non-COVID-19 ARDS cohorts that display signs of a cytokine storm [40]. It is important to note that IL-6 has several important anti-inflammatory as well as anti-viral functions [41]. Recent findings also suggest that in addition to an increase in pro-inflammatory mediator production there may also be disruptions in specific resolution pathways in patients with COVID-19 [42].

Coronavirus replication is generally associated with a delayed and dramatically reduced IFN induction in most cell types, and COVID-19 severity correlates with the degree of impairment [43, 44]. The ability to evade the innate immune response seems to be the highest for SARS-CoV-2, followed by SARS-CoV and MERS-CoV and, generally, human endemic CoVs are worse inhibitors than epidemic and pandemic viruses [45]. In the case of SARS-CoV, this leads to the dysregulated activation of the inflammatory monocyte–macrophage response, in turn causing vascular leakage and impaired B- and T-cell activation [46].

Data from patients who died from COVID-19 suggest that SARS-CoV-2 infects endothelial cells to cause inflammation (endothelialitis) [47]. This observed endothelialitis supports the hypothesis that SARS-CoV-2 has tropism for vascular endothelial cells, which express the ACE receptor [48]. Indeed, viral cytotoxicity is likely contributing to the pathogenesis of severe COVID-19, since post-mortem detection of replicating virus is common [49]. Direct endothelial damage could also explain the
multi-system organ failure and hypercoagulable state associated with severe COVID-19, since local pulmonary endothelialitis could result in activation of the coagulation cascade and exuberant production of endothelium-derived pro-inflammatory cytokines [50].

**Current therapies for viral pneumonia**

Approved anti-viral medications with activity against influenza viruses [51] are used as prophylactic adjuncts to the influenza vaccine to control the infection and/or as treatment to reduce symptoms from influenza (Table 2). Antiviral treatment is recommended as early as possible for any patient with confirmed or suspected influenza who are hospitalized, have severe, complicated, or progressive illness; or are at higher risk for influenza complications [51]. Antivirals may also be considered for healthy, symptomatic outpatients not at high risk for influenza complications, who are diagnosed with confirmed or suspected influenza, based on clinical judgment, if treatment can be initiated within 48 h of illness onset.

Neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) block enzymes that cleave sialic acid groups from glycoproteins, effectively preventing release of viral particles—virions—from the host cell [52]. These have activity against both Influenza A and B viruses, and are approved by the U.S. Food and Drug Administration (FDA) and by the European Center for Disease Prevention and Control [53]. Baloxavir is a cap-dependent

| Antiviral agent (trade name) | Activity against virus | Use | Safety and efficacy | References |
|------------------------------|-----------------------|-----|---------------------|------------|
| Oseltamivir (Tamiflu®)       | Influenza A and B     | Treatment | Accelerates time to clinical symptom alleviation, reduces risk of lower respiratory tract complications, and admission to hospital | [139], [140], [141], [142] |
|                              |                      | Chemoprophylaxis | Modest evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations | [141], [142] |
| Zanamivir (Relenza®)         | Influenza A and B     | Treatment | Decreases the risk of becoming symptomatic | [141], [143], [144], [145] |
|                              |                      | Chemoprophylaxis |                                                   | |
| Peramivir (Rapivab®)         | Influenza A and B     | Treatment | Reduces the time to alleviation of influenza symptoms | [146], [147] |
|                              |                      | Chemoprophylaxis |                                                   | |
| Baloxavir (Xofluza®)         | Influenza A and B     | Treatment | Effective in alleviating influenza symptoms and reducing the viral load 1 day after initiation | [148], [149], [150], [151], [57], [152] |
|                              |                      | Chemoprophylaxis |                                                   | |
| Laninamivir (Inavir®)        | Influenza A and B     | Treatment | Inhibited the NA activities, reduces duration of symptoms | [153], [154], [155], [56], [156], [55] |
|                              |                      | Chemoprophylaxis |                                                   | |
endonuclease inhibitor that interferes with viral RNA transcription and blocks virus replication [54] and has shown significant promise in a multicenter randomized clinical trial of post-exposure prophylaxis [55–57]. The adamantanes (amantadine, rimantadine) are antivirals that target the Influenza A virus M2 ion channel protein [58]. However, high levels of resistance (>99%) to adamantanes among circulating Influenza A (H3N2) and influenza A(H1N1)pdm09 (“2009 H1N1”) viruses preclude their recommendation for anti-viral treatment or chemoprophylaxis of currently circulating Influenza A viruses (for detailed discussion see [59]).

Multiple compounds are currently at various stages of investigation for influenza treatment [60–62]. The Influenza Therapeutics Program [63] is a major focus of BARDA (The Biomedical Advanced Research and Development Authority) [64]. Prior to the pandemic, the International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirvAVG) conference to review emerging therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses [65]. Multiple additional compounds are under investigation for the treatment of non-coronavirus, lower respiratory tract infections (Additional file 1: Table S1). In addition to potential toxicity and the rapid development of resistance, the limitation of anti-viral-directed therapy is that it obviates management of the response of the host to infection—a fundamental determinant of outcome in the development of ARDS [66–68].

In summary, while specific anti-viral therapies exist, they must be used early in the disease course to be effective. Their limited efficacy later in the infection process means that the cornerstone of management remains supportive care with respiratory support (oxygen, ventilatory assistance), rest, antipyretics, analgesics, nutrition, and close observation [65]. New therapies to directly attenuate viral-induced pneumonia and lung injury are a priority.

**MSCs—therapeutic potential for viral pneumonia**

MSCs have been proposed as a promising therapeutic strategy in viral pneumonia because they possess immunomodulatory, anti-microbial, and pro-resolution properties (Fig. 1) [2]. MSCs can be easily sourced from various tissue types, and while the MSC optimal tissue source remains unclear, bone marrow (BM) and umbilical cord (UC) derived MSCs may be more effective than adipose tissue derived MSCs in pre-clinical acute lung injury models [69].

**MSC administration kinetics**

Following systemic administration, MSCs are initially trapped in the lungs and subsequently ‘home’ and are retained in injured or inflamed areas [70]. Tracking studies utilizing radiolabelled or fluorescently labelled MSCs demonstrate MSCs lodge in the pulmonary vascular bed where they remain detectable for a few days with the majority of cells being cleared within 24–48 h although this may be prolonged in injured lungs [71, 72]. While in the pulmonary capillary bed, MSCs appear to ‘sense’ the surrounding inflammatory environment through cell surface damage and pathogen molecular pattern receptors [73–75] releasing a range of soluble elements of its ‘secretome’ in response.
MSC homing to sites of injury is mediated via chemokine receptors, adhesion proteins, and matrix metalloproteinase (MMPs) [76]. At injury sites, MSCs interact with target cells through cell-to-cell contact and paracrine/endocrine effects, the latter by secreting soluble mediators (including anti-inflammatory cytokines, antimicrobial peptides, and angiogenic growth factors) and extracellular vesicles (EVs), and/or by transferring organelles such as mitochondria to target immune cells (leukocytes [monocytes, macrophages, lymphocytes] and structural cells [including endothelial, epithelial, and smooth-muscle cells]) [77]. MSC-derived EVs contain proteins, lipids, mRNA, microRNAs, DNAs [78]. Mitochondrial transfer from MSCs can occur through tunnelling nanotubes (TNTs), gap junctions, or via EVs [1, 78–80].

Systemically administered MSCs may also undergo rapid tissue factor-mediated apoptosis in a phenomenon designated the ‘instant blood-mediated inflammatory response’ (IBMIR) [81]. The response of the host immune system to these dead or dying MSCs driving potential beneficial responses for the underlying lung injury [82]. This may be particularly relevant in both non-viral and viral-induced ARDS in the context of increasing recognition of different inflammatory ARDS phenotypes [83].

**Fig. 1** Mechanisms of action of MSCs which can counteract viral infection. (1) Viral infection leads to tissue damage at the delicate blood-air barrier in the lung. The release of inflammatory cytokines initiates further tissue damage with (2) inflammatory T-cell proliferation and differentiation to Th-1 and Th-17s, (3) inflammatory white cell recruitment from the blood and tissues leading to further inflammation, creation of neutrophil NETS, fibroblast differentiation, oedema fluid accumulation and significant barrier disruption. MSCs have been demonstrated to act on several of the injurious processes that occur in infection such as (4) Release of cytokines and chemokines which promote anti-inflammatory innate and adaptive cell phenotypes, (5) release of factors which prevent the formation of NETS, reduce barrier disruption, and (6) prevent fibroblast differentiation and promote PMN apoptosis. (7) MSC IL-10 production and production from anti-inflammatory monocytes induces regulatory B and T cells and promotes tissue protection and repair, and MSC IDO production regulates inflammatory T-cell proliferation.
Microenvironmental responsiveness and MSC pre-activation

MSCs respond to microenvironmental cues as demonstrated by their release of anti-inflammatory mediators when placed in an inflammatory lung environment [84]. This is mediated by MSC response to damage and pathogen-associated molecular patterns (DAMPs and PAMPs, respectively) [85]. MSC toll-like receptors (TLRs) 3 and 9 are activated by viral RNA and viral unmethylated CpG-DNA, respectively, leading to activation of downstream signalling pathways [2]. Recent reports have characterized MSCs responsiveness to the in vivo inflammatory lung environment by exposing them to either clinical bronchoalveolar lavage fluid (BALF) or serum samples from patients with ARDS [85–89]. Exposure of MSCs to a healthy lung environment (i.e., BALF obtained from healthy volunteers) induced expression of genes encoding for recognition as foreign to the host immune system and for inflammation [85]. In contrast, MSCs exposed to BALF samples from patients with cystic fibrosis or ARDS demonstrated disease-specific responses in gene and protein expression and in downstream effects on immune effector cells such as alveolar macrophages [85, 87, 89].

Pre-activation or ‘licencing’ of MSCs may enhance or direct their therapeutic potential by pre-exposure to conditions that mimic specific microenvironmental conditions [74, 85], or via approaches such as genetic modification [90].

Direct versus indirect MSC effects

Direct MSC effects may be mediated via cell–cell contact or via its secretome [91]. MSC soluble and insoluble extracellular products can be utilized in place of a whole cell therapy [92], facilitating delivery directly into the lung via nebulization [93, 94]. MSC-secreted angiopoietin-1 (Ang-1) and keratinocyte growth factor (KGF) enhance restoration of disrupted alveolar–capillary barrier, while specific regulatory mRNAs in EVs mediate the protective effects of MSCs in pre-clinical models of bacterial or non-infectious acute lung injuries [95, 96].

MSCs—insights from pre-clinical studies

There is a large body of literature demonstrating efficacy of either systemic or direct intratracheal (IT) MSC administration in pre-clinical models of acute pneumonia/pneumonitis and acute lung injury. Most of these studies involve acute lung injury induced by bacteria or bacterial products (endotoxin) or other means [97]. The models include both rodents, as well as large animals (pig, sheep) and explanted human lungs [98]. A range of approaches have been utilized for dose size, dosing route, and MSC source. In contrast, there are a relatively small number of pre-clinical studies investigating effects of MSC administration in pre-clinical models of respiratory virus infections.

MSC effects in viral pneumonia

Systemic MSC administration may reduce the chemokines responsible for lung leukocyte infiltration, such as granulocyte–macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1 alpha (MIP-1α). Antiviral immune responses include increased levels of
IFN-γ, which alone or together with pro-inflammatory cytokines activate MSCs to release anti-inflammatory mediators [99]. In vitro, MSCs suppress lymphocyte proliferation in response to the activation of influenza-specific T cells and inhibit the cytotoxicity of specific T cells against H1N1 influenza virus [100]. MSCs may also promote lung epithelial and endothelial cell repair, which may be associated with the anti-inflammatory, anti-apoptotic, and anti-oxidative effects of MSCs, thus promoting endothelial–epithelial barrier integrity, which helps the surfactant to recover followed by a decrease in alveolar oedema and atelectasis [101].

**Strain-dependent efficacy in influenza models**

MSC administration improved dysregulated alveolar fluid clearance and protein permeability induced by H5N1 and H7N9 influenza viruses in in vitro models, in part by releasing soluble mediators including Ang-1 and KGF that up-regulated sodium and chloride transporters [102]. In parallel studies, systemic administration of human bone marrow-derived MSCs 5 days after induction of H5N1 infection in aged, immunocompetent mice reduced virus-induced mortality, weight loss, lung oedema, BALF CD4+ T cells and natural killer (NK) cells, lung histopathological lesions, pro-inflammatory cytokines and chemokines in the absence of reducing lung virus titres. Notably, no effects were observed in mortality and body weight loss in young mice. These observations suggest that systemic MSC administration may provide benefit in older patients who are at higher risk for severe pulmonary illness caused by H5N1 influenza and also possibly SARS-CoV-2 infection.

Avian influenza virus infection can trigger a very intense pro-inflammatory response compared to other influenza viruses. Avian Influenza virus (H9N2) infection increases serum and lung levels of GM-CSF, MCP-1, MIP-1α and inflammatory leukocyte chemoattractants. In a pre-clinical model of H9N2-induced lung injury using young immunocompetent mice, a single systemic MSC administration (10^5 MSCs) 3 days after injury resulted in reduction in mortality, lung oedema, histologic injury, BALF and serum chemokines and cytokines (including MCP-1 and MIP-1α), and improved gas-exchange and increased anti-inflammatory mediator concentrations [103]. In another study, systemic administration of UC-MSCs were more effective than BM-MSCs when administered 5 days after induction of Influenza A (H5N1) infection in young female immunocompetent mice with respect to decreasing body weight loss, lung oedema, and inflammation [104]. However, neither type of MSC improved mortality or decreased virus titre. Nonetheless, this has provided one platform for use of UC-MSCs in large number of clinical investigations in COVID-19-induced ARDS.

Despite the potential for MSCs to be effective in the resolution of viral pneumonia, two studies found MSCs not to be protective against influenza respiratory infections in mice. In one, the effects of a single systemic administration in immunocompetent mice of either murine or xenogeneic human bone marrow-derived MSCs were assessed in lung injury induced by mouse-adapted H1N1 or swine-origin pandemic H1N1 [105]. Neither MSC administration, either alone or as an adjuvant therapy with oseltamivir, was effective either when administered prior to virus inoculation, or when therapeutically administered. In another study, neither systemic nor IT administration of 2 doses of MSCs (5 × 10^5 cells) improved H1N1-mediated lung injury [106].
MSCs in pre-clinical COVID-19
There are no pre-clinical data investigating effects of MSC administration in models of coronavirus respiratory infection, mostly due to the lack of an established animal model. SARS-CoV-2 replication was observed in several non-human primates and in inbred strains of mice following intranasal infection, but these models failed to show clinical signs of pulmonary disease as seen in humans [107]. Human ACE2-overexpressing transgenic mice infected with SARS-CoV-2 demonstrated interstitial pneumonia with lymphocyte and monocyte infiltration into the alveolar interstitium and accumulation of macrophages in alveolar spaces [108]. While these models require further evaluation, they may facilitate the testing of therapeutics including cell-based therapies for COVID-19. We can appreciate the promise of MSCs for the treatment of COVID-19 infection by taking what we know from pre-clinical studies using infectious reagents of bacterial and viral origin.

Cell-free therapies
MSCs-derived EVs have been demonstrated to have comparable and in some cases more effective than MSCs themselves in ameliorating inflammation and injury in a range of pre-clinical lung injury models [109, 110]. Systemic administration of porcine MSC-EVs was found to be safe and reduced virus shedding in nasal swabs, influenza replication in the lungs, BALF pro-inflammatory cytokines and chemokines, histopathological changes when administered 12 h after viral inoculation in a mixed swine (H3N2, H1N1) and avian (H9N5, H7N2) influenza-induced pig lung injury model [111]. These findings suggest systemic EV administration has therapeutic potential for respiratory virus-induced lung injuries.

Summary
There is a substantial pre-clinical literature examining the potential for MSCs to reduce lung injury, via effects that address injury mechanisms directly relevant to viral pneumonia. However, the data from pre-clinical studies of respiratory virus infections are limited to influenza viruses and have produced conflicting results. MSC-derived cell products, particularly EVs, demonstrate significant therapeutic promise.

MSCs—insights from clinical studies
MSC safety profile in clinical trials
A recent systematic review and meta-analysis of MSC therapy included 55 randomized control trials with 2696 patients [112] across a wide variety of clinical conditions. Other than an increased risk of pyrexia, no safety signals (including in relation to infection, thromboembolic events or malignancy) were reported. Furthermore, the risk of death was significantly lower in the MSC-treated group compared to controls. Further follow-up data are needed to determine the safety of MSCs in the longer term.

Clinical trials in ARDS and sepsis
Several ongoing and completed trials of MSCs for ARDS and sepsis support the investigation of MSCs in patients with viral pneumonia. These studies demonstrate
that MSC therapy in critically ill ARDS and sepsis patients is feasible and safe, albeit the numbers treated to date is small (see detailed review [113]). Two phase 2 studies in early ARDS demonstrate that MSCs were well tolerated [87, 114]. Post hoc analyses suggested patients with more severe impairment of oxygenation had a better treatment response [114] and that higher MSC viability was associated with greater improvements in Ang-2 and oxygenation [122]. Intravenous MSC therapy reduced lung permeability injury and lung injury severity versus placebo, decreasing mediators of lung injury, such as angiopoietin-2 [115].

**MSCs in viral pneumonia**

An observational study investigating the use of menstrual blood-derived MSCs in 17 patients with H7N9 viral-induced moderate-to-severe ARDS reported no safety issues [116]. Patients received a dose of $1 \times 10^6$ cells/kg MSCs on multiple (up to 4) occasions in early versus later phase ARDS. MSC therapy in COVID-19 patients has been reported in multiple small uncontrolled studies. There was significant heterogeneity in the population receiving MSCs as well as the regimens used in terms of dose and frequency of administration. In general, these studies reported no safety issues and promising efficacy data, however findings must be considered exploratory due to the many methodological limitations. Randomized controlled clinical trials of MSC therapy for COVID-19 are now being reported (Table 3). The dose used was variable and several of these trials tested multiple doses. Together these trials indicate that MSCs were well tolerated and showed promising efficacy in COVID-19 infection ([117–119] and NCT04371393). Other trials have recently completed recruitment and results are awaited [120]. Further larger trials are required to adequately assess the question of efficacy of MSCs in viral pneumonia.

| Study type/patient cohort | Intervention | Outcomes measured | Reference/trial number |
|--------------------------|--------------|-------------------|------------------------|
| Phase 2                 | UC-MSCs (VCANBIO) | Improvement in whole lung lesion volume, no difference in SAEs | Shi et al. [117] NCT04288102 |
| Severe COVID-19 induced ARDS (n=100, 2:1 ratio) | $4 \times 10^7$ MSCs $\times$ 3 infusions | No infusion associated AEs or SAEs, inflammatory cytokines decreased, improved patient survival, and time to recovery | Lanzoni et al. [118] NCT04355728 |
| Phase 1/2a               | UC-MSCs + Heparin | $1 \times 10^6$ MSCs $\times$ 2 infusions | Lanzoni et al. [118] NCT04355728 |
| Mild–moderate and moderate–severe COVID-19 induced ARDS (n=24, 1:1) |  |
| Phase 1                 | UC-MSCs + standard care | Improved survival rate, no changes in ICU stay or ventilator use, no AEs reported. IL-6 reduced | Dilogo et al. [119] NCT04457609 |
| Critically ill COVID-19 patients (n=40, 1:1) | $1 \times 10^6$ MSC/kg |  |
| Phase 3                 | BM-MSCs (Remestemcel-L) | 30-day all-cause mortality, ventilator-free days, adverse events, 7-day mortality, ARDS resolution | NCT04371393 Ongoing |
| Moderate-to-severe COVID-19 induced ARDS (n=223, 1:1) | $2 \times 10^6$ MSC/kg $\times$ 2 infusions |  |
| Phase 1/2               | UC-MSCs (Orbcell-C) Max tolerated dose established in Phase 1 | Oxygenation Index, SAE incidence | NCT03042143 Ongoing |
| Moderate-to-severe COVID-19 induced ARDS (n=120, 1:1) |  |  |
Table 4  Challenges for testing mesenchymal stromal cells for ARDS

| Challenge                              | Solutions/options                                                                 |
|----------------------------------------|-----------------------------------------------------------------------------------|
| Source and production methods          | Bone marrow, umbilical cord, iPSC-derived                                          |
| Optimal dose (intravenous)             | 2, 4, or 10 x 10^6/kg (ideal body weight)                                         |
| Number of doses and timing             | One dose versus two doses                                                          |
|                                        | Dose spacing 36–72 h apart?                                                       |
| Inclusion criteria                     | High-flow nasal oxygen versus invasive mechanical ventilation                      |
| Identifying treatment responsive phenotypes | Potential variables—age, viral, bacterial pneumonia, shock or not shock, biological variables (IL-8, Protein C, bicarbonate) |

**Future directions: opportunities and challenges**

While allogeneic MSCs demonstrate considerable therapeutic promise for severe viral pneumonia significant knowledge gaps and challenges remain (Table 4). Translation of MSCs to effective therapy in patients with severe viral pneumonia will require additional studies to determine: (1) the optimal MSCs therapeutic; (2) the optimal dose regimen; (3) the optimal patient population, and (5) the potential interaction of concomitant therapies.

**Optimal MSC therapeutic**

Allogeneic MSCs can be harvested from bone marrow, umbilical cord, and adipose tissue, and each of these MSC sources have been tested in small ARDS trials that reported no safety issues [121, 122]. MSCs derived from older donors may have impaired function [123]. Recently, MSCs that were produced with induced pluripotent stem cell (iPSC) technology were tested in a sheep model of severe pneumonia and sepsis over 48 h; based on a preliminary report, iP-MSCs markedly improved oxygenation and they reduced protein rich lung lymph flow indicating reduced lung vascular injury compared to placebo controls [124]. There is also pre-clinical work indicating that EVs derived from MSCs can deliver most of the biological cargo from MSCs and might be adapted for clinical treatment, currently being developed for therapy of premature infants with neonatal respiratory distress syndrome [125]. It is not possible at this time to determine the relative efficacy of the various sources of MSCs, although there is considerable interest in iPSC-derived MSCs as they might accelerate and simplify production providing there are no safety issues that emerge in pre-clinical studies, especially regarding oncogenic risk.

**Optimal MSC dosing regimen**

The optimal dosing regimen of MSCs for viral pneumonia is uncertain, and pre-clinical studies in small animals provide limited insights regarding dosing or timing of MSC therapy in the clinical setting. In pre-clinical studies, a dose-dependent effect, with greater efficacy seen with higher doses, has been frequently reported [126]. However, in a human LPS model, dose-dependent adverse effects were demonstrated at the highest dose investigated with enhanced febrile response and coagulation activation reported [127]. Furthermore, in a human study of diabetic nephropathy, 150 but not 300 million MSCs improved renal function [128]. Neither lower nor higher doses may
be optimal [129]. The dose used in phase 1 and 2a trials [121, 122], and an ongoing 2b clinical trial in ARDS (https://statttrial.com; password—StemCells4All NCT03818854) has been based on a study in a sheep bacterial pneumonia and sepsis model indicating that $10 \times 10^6$ MSC/kg was superior to $5 \times 10^6$ MSC/kg for reducing pulmonary oedema [130]. Other trials have used lower doses ranging from $2-4 \times 10^6$ MSCs/kg [114]. More studies will be needed to establish optimal dosing which may also depend on the source of the MSCs and their viability and potency. It is also possible that a higher dose may be needed for ARDS if the patient’s clinical course includes evidence of systemic injury with shock.

Frequency of MSC administration is a further consideration. Although studies in ARDS and sepsis have used a single intravenous infusion of MSCs, data emerging from studies in COVID-19 support efficacy with multiple doses. There is also some pre-clinical evidence to support multiple dosing regimens. A preliminary report in bacterial pneumonia and sepsis in sheep that showed efficacy of two intravenous doses of $10 \times 10^6$ i-MSCs/kg spaced 24 h apart [124]. The new evidence that MSCs can reduce biologic evidence of lung injury in BALF 48 h after intravenous administration of $10 \times 10^6$ MSCs/kg suggests that perhaps a second dose could be administered between 48 and 72 h to maximize efficacy, especially if the patient was not clinically improving by oxygenation and other pulmonary and systemic criteria.

A further challenge related to dosing regimens is that differing MSC products may not have consistent efficacy. A potency assay to standardize therapeutic efficacy of a dose would be an important development to allow direct comparison of MSC products, however at present this is not available.

**Optimal patient population**

The immunomodulatory effect of MSCs raises the potential that they may be more likely to exert therapeutic effects in the subgroup of patients with a dysfunctional pro-inflammatory response to viral infection. Proof-of-concept for this approach comes from research into patients with ARDS, where hypo- and hyper-inflammatory endotypes have been identified [131, 132] that respond differently to therapeutic interventions [133]. Calfee and colleagues reported that a parsimonious set of three biologic markers identified patients with higher mortality versus lower mortality for classical ARDS prior to COVID-19 (interleukin-8, Protein C, and bicarbonate), and this approach worked very well even in a re-analysis of the START-2 trial 60 patient trial of MSCs versus placebo [134]. Other approaches could include focusing on viral pneumonia patients with the highest mortality risk, which would include patients in shock requiring vasopressors. Another approach would be to use a radiographic severity score showing more pulmonary oedema with a RALE score greater than 20 for example, since higher RALE scores is an independent marker of higher mortality [135].

**Impairment of MSCs by viral infection**

A potential concern is that viruses may directly infect and impair MSC function due to their expression of receptors which allow the entry of several types of viruses. However, because MSCs are negative for the aACE2 and TMPRSS2 proteins, they are not susceptible to SARS-CoV-2 [136]. Therefore, MSCs would be safe and effective for treating
patients with COVID-19 pneumonia. CD147 is another entry receptor for SARS-CoV-2, expressed by tissue-specific stem cells [137] and certain pulmonary cells. Viral infection by either route and intracellular replication results in both loss of airway epithelial cells and regenerating stem cells, thus diminishing cellular and lung regeneration.

**MSCs use with concomitant therapy**

One final challenge relates to the potential interaction of concomitant therapies, particularly in the setting of COVID-19 pneumonia. Treatment with steroids is now standard of care for hospitalized patients with COVID-19 requiring oxygen therapy. However, there are data to suggest that steroids may attenuate the beneficial effects of MSCs which will have implications for the impact of MSCs in this setting [138].

**Summary and conclusions**

Mesenchymal stem cells display considerable promise for the treatment of more severe viral pneumonia, display potentially relevant mechanisms of action, and have a demonstrated safety profile in early phase studies, MSCS are currently being evaluated in multiple larger phase 2 clinical trials for COVID-19 pneumonia. Important insights will emerge from these studies in the coming months. Nevertheless, important knowledge gaps remain to be elucidated, including the optimal cell type, dose regimen and dose timing, as well as the optimal patient subpopulations for these therapies. There are also challenges to the scale-up of MSC production to conduct large phase 3 studies and for their eventual clinical use should they prove effective for the treatment of viral pneumonia. Further research aimed at optimizing the therapeutic potential of these MSCs for viral pneumonia will continue to be an important priority if we are to realise their therapeutic potential for this devastating condition.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40635-021-00424-5.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

All authors contributed to the writing of the original draft and to the critical revision of the manuscript for important intellectual content.

**Funding**

Science Foundation Ireland Future Research Leaders Award (16/FRL-3845) awarded to J. Laffey.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.
Competing interests
See COI forms for each author.

Author details
1 Anaesthesia, School of Medicine, National University of Ireland, Galway, Ireland. 2 Regenerative Medicine Institute, National University of Ireland, Galway, Ireland. 3 Critical Center, Corporacion Sanitaria Universitaria Parc Taulí, Autonomous University of Barcelona, Sabadell, Spain. 4 Keenan Center for Biomedical Research, St. Michael's Hospital, Bond St, Toronto, Canada. 5 Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 6 National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil. 7 Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden. 8 Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, USA. 9 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK. 10 Welcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. 11 Department of Medicine and Anesthesia, University of California, San Francisco, CA, USA. 12 Cardiovascular Research Institute, University of California, San Francisco, CA, USA. 13 Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland. 14 Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden. 15 Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, USA. 16 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK. 17 Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co. Kildare, Ireland. 18 Anaesthesia, School of Medicine, Royal College of Surgeons in Ireland, Dublin 9, Ireland. 19 Department of Anaesthesia and Intensive Care Medicine, Galway University Hospitals, Saolta University Hospital Group, Galway, Ireland.

Received: 11 October 2021   Accepted: 21 November 2021

Published online: 31 December 2021

References
1. Abreu SC, Lopes-Pacheco M, Weiss DJ, Rocco PRM (2021) Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Lung Diseases: Current Status and Perspectives. Front Cell Dev Biol 9:600711
2. Khoury M, Cuencán J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ (2020) Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J 55:8
3. Jain S, Self WH, Wunderink RG, Team CES (2015) Community-Acquired Pneumonia Requiring Hospitalization. N Engl J Med 373:2382
4. Choi SH, Hong SB, Ko GB, Lee Y, Park HJ, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Huh JW, Sung H, Do KH, Lee SO, Kim MN, Jeong JY, Lim CM, Kim YS, Woo JH, Koh Y (2012) Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 186:325–332
5. Centers for Disease Control and Prevention NCIFaRDN (2021) Burden of Influenza. Book Burden of Influenza, New York
6. Iuliano AD, Rogowski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, Wu P, Knych J, Ang LW, Park M, Redlibberger-Fritz M, Yu H, Esperhain L, Krishnan A, Emukule G, van Asten L, Pereira da Silva S, Aungkulanon S, Buchholz U, Widdowson MA, Breee JS, Collaborator G-A, N, (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391:1285–1300
7. Babcock HW, Merz LR, Fraser VJ (2006) Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 27:266–270
8. Chow EJ, Doyle JD, Uyeki TM (2019) Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care 23:214
9. Ramsey CD, Kumar A (2013) Influenza and endemic viral pneumonia. Crit Care Clin 29:1069–1086
10. Dandachi D, Rodriguez-Barradas MC (2018) Viral pneumonia: etiologies and treatment. J Invest Med 66:957–965
11. Murray CJ, Lopez AD, Chin HH, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, Wu P, Knych J, Ang LW, Park M, Redlibberger-Fritz M, Yu H, Esperhain L, Krishnan A, Emukule G, van Asten L, Pereira da Silva S, Aungkulanon S, Buchholz U, Widdowson MA, Breee JS, Collaborator G-A, N, (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391:1285–1300
12. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA, Influenza IWGo, (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361:680–689
13. Writing Committee of the WHOCoCAoPI, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362:1708–1719
14. To KK, Chan JF, Yuen KY (2014) Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A(H7N9). Curr Opin Pulm Med 20:225–232
15. Peiris JS, Yuen KY, Osterhaus AD, Stohr K (2003) The severe acute respiratory syndrome. N Engl J Med 349:2431–2441
16. Lee N, Qureshi ST (2013) Other viral pneumonias: coronavirus, respiratory syncytial virus, adenovirus, hantavirus. Crit Care Clin 29:1045–1068
17. Zaki SR, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820
18. WHO (2021) Middle East respiratory syndrome coronavirus (MERS-CoV). In: Book Middle East respiratory syndrome coronavirus (MERS-CoV)
19. Medicine JHU (2021) Coronavirus Resource Center - Global Map. In: Book Coronavirus Resource Center - Global Scans, Map
20. Network C-IGobotR, the C-ICUI (2021) Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 47:60–73
21. Grasselli G, Greco M, Zanella A, Albanese G, Antonelli M, Bellani G, Bonanini E, Cabrini L, Carlesso E, Castelli G, Cateriano S, Cerisola D, Coombes S, Collecuolo A, Cresciini G, Forastieri Molinari A, Foti G, Fumagalli R, Iotti GA, Langer T, Latronico N, Lorini FL, Mogili F, Natalini G, Pessina CM, Ranieri VM, Rech R, Scudeller L, Rosano A, Storti E, Thompson BT, Tirani M, Villani PG, Piesenti A, Cecconi M, Network C-LI (2020) Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med 180:1345–1355

22. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:934–943

23. Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, Billah B, Ashwin S, Kubicki M, Bilotta F, Curtis JR, Rubulotta F (2021) Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation: a meta-analysis. Am J Respir Crit Care Med 203:54–66

24. Jang C, Flaatten H, Fjolner J, Bruno RR, Wernly B, Artigas A, Bollen-Pinto B, Schefold JC, Wolff G, Kelm M, Beil M, Sviri H, Gonzalez J, Benitez ID, Carmona P, Santisteve S, Monge A, Moncusi-Moix A, Gort-Paniello C, Pinilla L, Carratala A, et al. (2020) Risk Factors and Clinical Impact of Fibrotic-Like Changes and the Organizing Pneumonia Pattern in Patients with COVID-19 and Non-COVID-19-induced Acute Respiratory Distress Syndrome. Arch Bronconeumol 23:9

25. Matthay MA, Zemann RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, Herridge M, Randolph AG, Calfee CS, et al. (2019) Acute respiratory distress syndrome. Nat Rev Dis Primers 5:18

26. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, Arledge KC, Chen YH, Zhang L, Wang X, et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181:271–280

27. Hoffmann M, Klein-Winter M, Wramer F, Symons CA, Hany T, Richter M, Ruprecht CR, Kruger N, Heinz L, Kaspar H, Gromeier M, Gagnon Y, Klenk HD, Drosten C, Pfeffer K, Henze M, Heidenreich T, et al. (2020) SARS-CoV-2 Cell Entry and Virus Replication are Blocked by a Clinically Proven Protease Inhibitor. Cell 181:271–280

28. Meyerholz DK, Lambertz AM, McCray PB Jr (2016) Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol 186:78–86

29. Hoffmann M, Kleine-Winter M, Scharf R, Kruger N, Heinz L, Richter M, Schlegels P, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pfeffer K, Henze M, Klenk HD, Drosten C, et al. (2020) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:986–993

30. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 101:4620–4624

31. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, Arledge KC, Chen YH, Zhang L, Wang X (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:986–993

32. Meyerholz DK, Lambertz AM, McCray PB Jr (2016) Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol 186:78–86

33. Hoffmann M, Kleine-Winter M, Scharf R, Kruger N, Heinz L, Richter M, Schlegels P, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pfeffer K, Henze M, Klenk HD, Drosten C, et al. (2020) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:986–993

34. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88:1293–1307

35. Clementi N, Ghosh S, De Santis M, Castelli M, Criscuolo E, Zanoni I, Clementi M, Mancini N (2021) Viral Respiratory Pathogens and Lung Injury. Clin Microbiol Rev 34:87

36. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, Ni Choileain O, Clarke J, O'Connor PM, et al. (2021) Interleukin-6: obstacles to targeting a complex inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med 202:812–821

37. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Xiao Z, Xiao J, Ning Q (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130:2620–2629

38. Schulten GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, Zhang K, Davis K, Jentzen JM, Napolitano L, Siddiqui J, Smith LB, Harms PW, Grom AA, Cron RQ (2016) Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza. J Infect Dis 213:1180–1188

39. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Collaboration HAS, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034

40. Sinha R, Matthay MA, Calfee CS (2020) Is a“Cytokine Storm” Relevant to COVID-19? JAMA Intern Med 180:1152–1154

41. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG (2021) Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med 9:643–654

42. Palmas F, Clarke J, Colas RA, Gomez E, Osorio A, Boylan M, McEvoy N, McElvaney OJ, McElvaney O, Alalqam R, McElvaney NG, Curley GF, Dalil J (2021) Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. PLoS ONE 16:e0256226
43. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uh I, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR (2020) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181:1036–1045
44. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M, Wang J (2020) Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe 27:883–890
45. Shuai H, Chu H, Hou Y, Yang D, Wang Y, Hu B, Huang X, Zhang X, Chai Y, Cai JP, Chan JF, Yuen KY (2020) Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-beta and IFN inducer. J Infect 81:e1–e10
46. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S (2016) Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 19:181–193
47. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laengfer F, Vanstapel A, Werlein C, Stark H, Tzanekou A, Li WW, Li VW, Mentzer SJ, Jonigk D (2020) Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med 383:120–128
48. Hamming I, Timens W, Bulters ML, Lely AT, Navis G, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637
49. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moeh H (2020) Endothelial cell infection and endothelitis in COVID-19. Lancet 395:1417–1418
50. Ward SE, Fogarty H, Karampini E, Lavin M, Schnepfenheim S, Dittmer R, Morrin H, Glavey S, Ni Cheallaigh C, Bergin T, Martin-Loeches I, Mallon PW, Curley GF, Baker RL, Buddle U, O'Sullivan JM, Krish JS (2021) ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 19:1914–1921
51. Prevention CCfDPa (2021) Influenza (Flu) For Clinicians: Antiviral Medication. In: Book Influenza (Flu) For Clinicians: Antiviral Medication
52. Bai Y, Jones JC, Wong SS, Zanin M (2021) Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance. Viruses 13:3
53. Control EECfDPa (2017) Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza. In: Book Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza. ECDC
54. Hayden FG, Shindo N (2019) Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 32:176–186
55. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S (2017) Duration of fever and other symptoms after the inhalation of palivizumab. J Pediatr 183:414–415.e1
56. Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG (2020) Early treatment with IFN-beta and IFN inducer. J Infect 81:e1–e10
57. Mtambo SE, Amoako DG, Somboro AM, Agoni C, Lawal MM, Gumede NS, Khan RB, Kumalo HM (2021) Influenza Infection and Thrombosis. J Infect Chemother 27:234–242
58. Herold S, Hoegner K, Vadasz I, Gessler T, Wilhelm J, Mayer K, Morty RE, Walmrath HD, Seeger W, Lohmeyer J (2014) Intravenous administration of recombinant human granulocyte-macrophage colony stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 189:609–611
59. Paine R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, Thannickal VJ, Burnham EL, Brown MB, Hyzy RC (2012) A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40:90–97
60. Halstead ES, Umstead TM, Davies MI, Kawasawa YI, Silveira P, Howyrlik J, Yang L, Guo W, Hu S, Hewage EK, Chenees ZC (2018) GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte/macrophage polarization. Respir Res 19:3
61. Services. USDoHH (2019) Influenza Therapeutics Program. In: Book Influenza Therapeutics Program
62. Services. USDoHH (2019) Influenza & emerging infectious diseases. In: Book influenza & emerging infectious diseases
63. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (2019) Advances in respiratory virus therapeutics and Mechanisms of Antiviral Resistance. Curr Med Chem 25:5115–5127
64. Weis S, TeVelthuis AJW (2021) Influenza Virus RNA Synthesis and the Innate Immune Response. Viruses 13:8
65. Bahadoran A, Bezavada L, Smallwood HS (2018) Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Curr Med Chem 25:5115–5127
66. Harold S, Hoegner K, Vadasz I, Gessler T, Wilhelm J, Mayer K, Morty RE, Walmrath HD, Seeger W, Lohmeyer J (2014) Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 189:609–611
67. Paine R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, Thannickal VJ, Burnham EL, Brown MB, Hyzy RC (2012) A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40:90–97
68. Halstead ES, Umstead TM, Davies MI, Kawasawa YI, Silveira P, Howyrlik J, Yang L, Guo W, Hu S, Hewage EK, Chenees ZC (2018) GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte/macrophage polarization. Respir Res 19:3
69. McIntyre LA, Moher D, Fergusson DA, Sullivan KJ, Mei SH, Lalu M, Marshall J, McLeod M, Griffin G, Grimshaw J, Turgeon A, Avey MT, Rudnicki MA, Jazi M, Fishman J, Stewart DJ, Biology CCCT, G, (2016) Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic Review. PLoS ONE 11:e0147170
70. Masterson CH, Curley GF, Laffey JG (2019) Modulating the distribution and fate of exogenously delivered MSCs to enhance therapeutic potential: knowns and unknowns. Intensive Care Med Exp 7:41
71. Masterson CH, Tabuchi A, Hogan G, Fitzpatrick G, Kerrigan SW, Jerkic M, Kuebler WM, Laffey JG, Curley GF (2021) Intra-vital imaging of mesenchymal stromal cell kinetics in the pulmonary vasculature during infection. Sci Rep 11:5265
72. Armitage J, Tan DBA, Troedson R, Young P, Lam KV, Shaw K, Sturm M, Weiss DJ, Moodley YP (2018) Mesenchymal stromal cell infusion modulates systemic inflammatory responses in stable COPD patients: a phase I pilot study. Eur Respir J 51:8
73. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5:e10088
74. Kusuma GD, Cartihe J, Lim R, Frith JE (2017) Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect. Stem Cells Dev 26:617–631
75. Islam D, Huang Y, Fanelli V, Delsedime L, Wu S, Khang J, Han B, Grassi A, Li M, Xu Y, Luo A, Wu J, Liu X, McKillop M, Medin J, Qiu H, Zhong N, Liu M, Laffey J, Li Y, Zhang H (2019) Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury. Am J Respir Crit Care Med 199:1214–1224
76. Ullah M, Liu DQ, Thakor AS (2019) Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. Science 15:421–438
77. Murray LMA, Krasnodembskaya AD (2019) Concise Review: Intercellular Communication Via Organelle Transfer in the Biology and Therapeutic Applications of Stem Cells. Stem Cells 37:14–25
78. Maron-Gutierrez T, Rocco PRM (2020) Cell-Free Therapies: Novel Approaches for COVID-19. Front Immunol 11:583017
79. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, Rowlands DJ, Quadri SK, Bhattacharya S, Bhattacharya J (2012) Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18:759–765
80. de Carvalho LRP, Abreu SC, de Castro LL, Andrade da Silva LH, Silva PM, Vieira JB, Santos RT, Cabral MR, Khoury M, Weiss DJ, Lopes-Pacheco M, Silva PL, Cruz FF, Rocco PRM (2021) Mitochondrion-Rich Fraction Isolated From Mesenchymal Stromal Cells Reduces Lung and Distal Organ Injury in Experimental Sepsis. Crit Care Med 49:2886
81. Moll G, Ozeneik N, Khoury M, Kayne J, Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P (2020) MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol 11:1091
82. Weiss DJ, English K, Krasnodembskaya A, Isaza-Corea JM, Hawthorne JJ, Mahon BP (2019) The Necrobiosis of Mesenchymal Stromal Cells Affects Therapeutic Efficacy. Front Immunol 10:1228
83. Reddy K, Calfee CS, McCauley DF (2021) Acute Respiratory Distress Syndrome Subphenotypes beyond the Syndrome: A Step toward Treatable Traits? Am J Resp Crit Care Med 203:1449–1451
84. Horie S, Gaynard S, Murphy M, Barry F, Scully M, O’Toole D, Laffey JG (2020) Cytokine pre-activation of cryopreserved xenogeneic-free human mesenchymal stromal cells enhances resolution and repair following ventilator-induced lung injury potentially via a KGF-dependent mechanism. Intensive Care Med Exp 8:8
85. Rolandascon Enes S, Hampton TH, Barua J, McKenna DH, Dos Santos CC, Amiel E, Ashare A, Liu KD, Krasnodembskaya AD, English K, Stanton BA, Rocco PRM, Matthay MA, Weiss DJ (2021) Healthy versus inflamed lung environments differentially effect MSCs. Eur Respir J 7:789
86. Bustos ML, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg YS, Sciarba J, Mroz L, McVerry BJ, Ellis BM, Kaminski N, Rojas M (2013) Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med 2:884–895
87. Abreu SC, Rolandascon Enes S, Dearborn J, Goodwin M, Coffey A, Bong ZD, Dos Santos CC, Wargo MJ, Cruz FF, Loi R, DeSarno M, Ashikaga T, Antunes MA, Rocco PRM, Liu KD, Lee JW, Matthay MA, McKenna DH, Weiss DJ (2019) Lung inflammatory environments differentially alter mesenchymal stromal cell behavior. Am J Physiol Lung Cell Mol Physiol 317:L823–L831
88. Abreu SC, Xisto DG, de Oliveira TB, Blanco NG, de Castro LL, Kitoko JZ, Olsen PC, Lopes-Pacheco M, Morales MM, Weiss DJ, Rocco PRM (2019) Serum from Asthmatic Mice Potentiates the Therapeutic Effects of Mesenchymal Stromal Cells in Experimental Allergic Asthma. Stem Cells Transl Med 8:301–312
89. Abreu SC, Hampton TH, Hoffman E, Dearborn J, Ashare A, Singh Sidhu K, Matthews DE, McKenna DH, Weiss DJ, Rolandascon Enes S (2020) Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells. Am J Physiol Lung Cell Mol Physiol 319:L908–L925
90. Noronha NC, Mizukami A, Caliari-Oliveira C, Cominal JG, Rocha JLM, Covas DT, Swiech K, Malgrém KCR (2019) Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther 10:131
91. Hayes M, Curley GF, Masterson C, Devaney J, O’Toole D, Laffey JG (2015) Mesenchymal stromal cells are more effective than the MSC secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury. Intensive Care Med Exp 3:29
92. Eleuteri S, Fierabracci A (2019) Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications. Int J Mol Sci 20:7
93. McCarthy SD, Horgan E, Ali A, Masterson C, Laffey JG, MacLoughlin R, O’Toole D (2020) Nebulized Mesenchymal Stem Cell Derived Conditioned Medium Retains Antibacterial Properties Against Clinical Pathogen Isolates. J Aerosol Med Pulm Drug Deliv 33:140–152
94. Shi M-M, Yang Q-Y, Monsel A, Yan J-Y, Dai C-X, Zhao J-Y, Shi G-C, Zhou M, Zhu X-M, Li S-K, Li P, Wang J, Li M, Lei J-G, Xu D, Zhu Y-G, Qu J-M (2021) Preclinical efficacy and clinical safety of clinical-grade nebulized allogeneic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracellular Vesicles 10:e12134
95. Lee JW, Krasnodembskaya A, Matthay MA (2013) Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 187:751–760
96. Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Roszenwajg M, Matthay MA, Lee JW (2015) Therapeutic Effects of Human Mesenchymal Stromal Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med 192:324–336
97. Cruz FF, Weiss DJ, Rocco PR (2016) Prospects and progress in cell therapy for acute respiratory distress syndrome. Expert Opin Biol Ther 16:1353–1360
98. Laffey JG, Matthay MA (2017) Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value. Am J Respir Crit Care Med 196:266–273
99. Pocheche O, Solinsky K, Douglas G, Kidd M, Moaasin A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745–1755
100. Liu X, Feng T, Gong T, Shen C, Zhu T, Wu Q, Li Q, Li H (2015) Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9δT Lymphocytes In Vitro. Biomed Res Int 2015:371801
101. Monguio-Tortajada M, Bayes-Genis A, Rosell A, Roura S (2021) Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives. Thorax 76:196–200
102. Chan MC, Kuck DJ, Leung CY, Hui KP, Valkenburg SA, Lau EH, Nicholls JM, Fang X, Guan Y, Lee JW, Chan RW, Webster RG, Matthay MA, Peiris JS (2016) Human mesenchymal stromal cells reduce influenza A HSN1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A 113:3621–3626
103. Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, Wu X, Han X, Liu Y, Wei Q, Qin C (2020) Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369:818–823
104. Loy H, Kuck DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, Peiris JSM, Chan MCW (2019) Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury. J Infect Dis 219:186–196
105. Darwish I, Dubeareka S, Kim H, Besral A, Kelvin DJ, Kaun KC, Liles WC (2013) Mesenchymal stromal cell therapy fails to improve outcomes in experimental severe influenza. PLoS ONE 8:e71761
106. Gotts JE, Abbott J, Matthay MA (2014) Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy. Am J Physiol Lung Cell Mol Physiol 307:L395-406
107. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Song Z, Liu Y, Zhao W, Han Y, Liu X, Wei Q, Qin C (2020) The pathogenicity of SARS-CoV-2 in HACE2 transgenic mice. Nature 583:830–833
108. Abreu SC, Weiss DJ, Rocco PR (2016) Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? Stem Cell Res Ther 7:53
109. Phelps J, Sanati-Nezhad A, Ugrin M, Duncan NA, Sen A (2018) Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics. Stem Cells Int 2018:9415367
110. Khatri M, Richardson LA, Meula T (2018) Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther 6:58
111. Thompson M, Mei SHJ, Wolfe D, Compagnie J, Ferguson D, Stewart DJ, Sullivan KJ, Doxtator E, Fergusson D, Champagne J (2021) Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med 8:563
112. Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, Young D, Bentley A, McVerry BJ, Wunderlich T, Kispa T, Mujadid F, Novialdi N, Luviah E, Kurniawati T, Lubis AMT, Rahmatika D (2021) Umbilical cord mesenchymal stem cells as critical COVID-19 adjuvant therapy: A structured summary of a study protocol for a randomised, controlled trial. Trials 21:462
121. Wilson JG, Liu KD, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA (2015) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3:24–32

122. Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Omtz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD (2019) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7:154–162

123. Bustos ML, Huleihel L, Kapetanaki MG, Lino-Cardenas CL, Mroz L, Ellis BM, McVerry BJ, Richards TJ, Kaminski N, Cerdenes N, Mora AL, Rojas M (2014) Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response. Am J Respir Crit Care Med 189:767–798

124. Hashimoto KB, Enkhbaatar P, Angel M, Lader A, Czuczman M, Matthay MA (2021) Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep. Cytotherapy 23:5

125. Lee JW, Matthay MA (2019) Is a part better than the whole for cell-based therapy for acute respiratory distress syndrome? Anesthesiology 130:683–685

126. Devaney J, Horie S, Masterson C, Elliman S, Barry F, O’Brien T, Curley GF, O’Toole D, Laffey JG (2015) Human Mesenchymal Stem Cells Modifies the Host Response to Lipopolysaccharide in Humans: A Randomized, Single-Blind, Parallel Group, Placebo Controlled Trial. Stem Cells 36:1776–1788

127. Perlee D, van Vught LA, Scicluna BP, Maag A, Lutter R, Kemper EM, van ‘t Veer C, Punchard MA, Gonzalez J, Richard MP, Dalemans W, Lombardo E, de Vos AF, van der Poll T, (2018) Intravenous Infusion of Human Adipose Mesenchymal Stem Cells Modifies the Host Response to Lipopolysaccharide in Humans: A Randomized, Single-Blind, Parallel Group, Placebo Controlled Trial. Stem Cells 36:1776–1788

128. Kabat M, Bobkov I, Kumar S, Grumet M (2020) Trends in mesenchymal stem cell clinical trials 2004–2018: Is efficacy optimal in a narrow dose range? Stem Cells Transl Med 9:17–27

129. Asmussen S, Io H, Traber DL, Liu KD, Matthay MA, Enkhbaatar P (2014) Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 70:625–635

130. Packham DK, Fraser IR, Kerr PG, Segal KR (2016) Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. FibroMedicine 12:263–269

131. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakraborti S, Min KJ, Ellison-Hughes C, Caruso C, Jin K, Zhao RC, (2020) Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis 11:216–228

132. Sinha P, Delucchi KL, McAuley DF, O’Kane CM, Matthay MA, Calfee CS (2020) Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med 8:247–257

133. Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, Matthay MA, Calfee CS, Ware LB (2018) Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 73:840–846

134. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakraborti S, Min KJ, Ellison-Hughes C, Caruso C, Jin K, Zhao RC (2020) Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis 11:216–228

135. Ulrich H, Pillat MM (2020) CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep 16:434–440

136. Dobson J, Whitley RJ, Pocock S, Monto AS (2015) Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385:1729–1737

137. Ebell MH, Call M, Shinholser J (2013) Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 30:125–133

138. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (2014) Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2547

139. Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, Pahud B, DeBiasi RL, Yamamoto G, Bajwa EK, Donahoe MP, McVerry BJ, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD (2019) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7:154–162

140. Butler D (2014) Tamiflu report comes under fire. Nature 508:439–440

141. Michiels B, Van Puyenbroeck X, Verhoeven V, Vermeire E, Coenen S (2013) The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS ONE 8:e60348

142. Ebell MH, Call M, Shinholser J (2013) Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 30:125–133

143. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (2014) Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2547

144. Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, Pahud B, DeBiasi RL, Yamamoto G, Bajwa EK, Donahoe MP, McVerry BJ, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD (2019) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7:154–162

145. Matthay MA, Arabi YM, Siegel ER, Ware LB, Bos LD, Sinha P, Beitler JR, Wick KD, Curley MAQ, Constantin JM, Levitt JE, McAuley DF, O’Kane CM, Matthay MA, Calfee CS (2020) Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med 8:247–257

146. Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, Matthay MA, Calfee CS, Ware LB (2018) Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 73:840–846
146. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J, Group SCS (2011) Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55:5267–5276

147. Thorlund K, Awad T, Boivin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11:134

148. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsujiyaka K, Uehara T, Watanabe A, Baloxavir Marboxil Investigators G (2018) Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 379:913–923

149. Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA (2020) Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J 39:700–705

150. Yokoyama S, Sakaguchi H, Ishibashi T, Shishido T, Piedra PA, Sato C, Tsujiyaka K, Uehara T (2020) Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study. Pediatr Infect Dis J 39:706–712

151. Ikematsu H, Hayden FG, Kawaguchi N, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsujiyaka K, Uehara T (2020) Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 383:309–320

152. Yoshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T (2018) Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clin Drug Investig 38:1189–1196

153. Nakano T, Yamaguchi H, Chiba T, Shiosakai K, Chikada S, Matsuoka Y (2021) The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance. J Infect Chemother 27:1436–1446

154. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, Group MS (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51:1167–1175

155. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53:186–192

156. Hirotsu N, Saisho Y, Hasegawa T, Shishido T (2018) Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4–12 years): an open-label, randomized study in Japan. Expert Rev Anti Infect Ther 16:173–182

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.